• Takeda Pharmaceutical
  •  Overview
  • Last Modified:
  • April 3, 2025
  • Company type:
  • Public
  • Industry:
  • Pharmaceutical
  • Verified:
  • No
  • No of Employees:
  • 10 001 - 50 000
  • Stock Code:
  • 4502
  • Download
  • Signed Health Status Declaration Form
  • Turnover $50m + ?:
  • Yes
  • Headquarters:
  • Japan
  • Public Interest Score:
  • 750+

 

  • Takeda Pharmaceutical
  • General Information

Description

Takeda Pharmaceutical is a global, values-based, patient-focused, R&D-driven biopharmaceutical company with a 240-year history, committed to bringing better health and a brighter future to people worldwide, focusing on areas like oncology, gastroenterology, and diabetes.

  • Focus Areas:

    They focus on oncology, gastroenterology, diabetes, and rare diseases, including hemophilia and lysosomal storage disorders. 

  • Global Presence:

    Takeda is a global company with a strong presence in Japan, and operates in various countries, including India and South Africa. 

  • History:

    The company traces its roots back to 1781, when Chobei Takeda I began selling traditional Japanese and Chinese herbal medicines in Osaka, Japan. 

  • Values:

    Takeda’s four business principles are patient, trust, reputation, and business, in that order, guiding their decisions. 

  • Corporate Social Responsibility (CSR):

    Takeda emphasizes Global Corporate Social Responsibility (CSR), focusing on strengthening health systems, improving access to care and supplies, and addressing food insecurity for vulnerable populations. 

  • Partnerships:

    Takeda has partnered with organizations like the World Food Programme (WFP) to address global health challenges and strengthen public health supply chains. 

  • Products:
    Takeda’s product portfolio includes medicines for various conditions, including ACTOS (pioglitazone), BUMINATE® 5% [Albumin (Human)], CARBATROL®(carbamazepine), DEXILANT (dexlansoprazole), ELAPRASE® (idursulfase) injection, FEIBA® (anti-inhibitor coagulant complex), and GAMMAGARD LIQUID® [Immune Globulin Infusion (Human)]. 
Christophe Weber:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Milano Furuta:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Costa Saroukos:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Masami Lijima:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Oliver Buhuon:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Jean-Luc Butel:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
John Maraganore:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Miki Tsusaka:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Koji Hatsukawa:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Kimberly Reed:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Andrew Plump:
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No
Ian Clark (Takeda):
qone: No, qtwo: No, qthree: No, qfour: No, qfive: No, qsix: No

Subsribe/ Login to view details on company risk rating

Subscribe / Login

 

5 Benchmark > 4 Excellent > 3  Good > 2 Caution > 1 Risk

 

  • Company Information
  • Company System Number:
  • 15598
  • Founded Year: 
  • 1781
  • Registration Number: 
  • 03925319
  • Country: 
  • Japan
  • Stock Exchanges: 
    • Tokyo Stock Exchange
    • New York Stock Exchange
    • Fukuoka Stock Exchange
  • Financial year end: 
  • March
  • No. of Countries operations: 
  • 70
  • Company Status: 
  • In Business
  • Industry Sub Category: 
  • Date listed on Stock Exchange: 
  • 01/05/1949

 

  • Contact Information
  • Business operation: 
  • Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.
  • Primary office: 
  • 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo. 103-8668, Japan

 

  • Additional Information
  • Listed?: 
  • Yes
  • Company secretary: 
  • Yoshihiro Nakagawa
  • Reporting currency: 
  • JPY
  • ISIN number (12 digit): 
TYO
JP3463000004
NYSE
US8740602052
FSE
JP3463000004
  • Authorised shares:
  • 3 500 000 000
  • Issued shares:
  • No of shareholders:
  • 1001 and more shareholders
  • No of shareholders holding 20%:
  • 0 shareholders
  • Number of shares traded
  • Per Year:
  • Per Quarter:
  • Per Month:

 

Subscribe/ Login to view more details on Health Status 

Subscribe / Login

 

Shareholders holding 5% +


For a comprehensive list, please contact InsidEntity.

Material Subsidiaries/Associates


For a comprehensive list, please contact InsidEntity.

Credit Rating

NameLogoCountryHeadquartersRating
Moody's RatingsCredit LogoUnited States of AmericaNew YorkBaa1

 

Countries Operations/ Offices


 

Company Directors

Name
Nationality
Age
Role
Qualification
Name

Christophe

Executive
NationalityFrance
59
RoleCEO
QualificationPharmD
Date Appointed: 01/04/2015
Duration:
11 years and 5 months
Independance: N
Profile
Name

Milano

Executive
NationalityJapan
RoleCFO
QualificationMBA
Date Appointed: 01/01/2015
Duration:
11 years and 8 months
Independance: N
Profile
Name

Costa

Executive
NationalityAustralia
55
RoleCFO
QualificationBcom Accounting
Date Appointed: 01/03/2018
Duration:
8 years and 6 months
Independance: Y
Profile
Name

Masami

Non Executive
NationalityJapan
75
RoleChairman
QualificationNot Available
Date Appointed: 01/06/2022
Duration:
4 years and 3 months
Independance: Y
Profile
Name

Oliver

Non Executive
NationalityFrance
67
RoleNED
QualificationPhD, MBA
Date Appointed: 01/01/2019
Duration:
7 years and 8 months
Independance: Y
Profile
Name

Jean-Luc

Non Executive
NationalitySingapore
70
RoleNED
QualificationBA, MBA
Date Appointed: 01/01/2019
Duration:
7 years and 8 months
Independance: Y
Profile
Name

John

Non Executive
NationalityAmerican
64
RoleNED
QualificationB.A, M.S, Ph.D Biochemistry and Molecular Biology
Date Appointed: 01/06/2022
Duration:
4 years and 3 months
Independance: Y
Profile
Name

Miki

Non Executive
NationalityJapan
63
RoleNED
QualificationAB, MBA
Date Appointed: 01/01/2023
Duration:
3 years and 8 months
Independance: Y
Profile
Name

Koji

Non Executive
NationalityJapan
71
RoleNED
QualificationNot available
Date Appointed: 01/06/2016
Duration:
10 years and 3 months
Independance: N
Profile
Name

Yoshiaki

Non Executive
NationalityJapan
75
RoleNED
QualificationBachelors Petroleum Engineering, MBA
Date Appointed: 01/06/2016
Duration:
10 years and 3 months
Independance: N
Profile
Name

Kimberly

Non Executive
NationalityAmerican
55
RoleNED
QualificationBS, BA, JD
Date Appointed: 01/06/2022
Duration:
4 years and 3 months
Independance: Y
Profile
Name

Andrew S

Executive
NationalityAmerican
RolePresident
QualificationM.D., Ph.D
Date Appointed: 01/01/2015
Duration:
11 years and 8 months
Independance: N
Profile
Name

Ian

Non Executive
NationalityAmerican
RoleNED
QualificationDoctorate degree in biological sciences
Date Appointed: 01/01/2019
Duration:
7 years and 8 months
Independance: Y
Profile

 

Directors Tenure

Name
Duration
Name

Christophe Weber

Duration11 years and 5 months
Profile
Name

Milano Furuta

Duration11 years and 8 months
Profile
Name

Costa Saroukos

Duration8 years and 6 months
Profile
Name

Masami Lijima

Duration4 years and 3 months
Profile
Name

Oliver Buhuon

Duration7 years and 8 months
Profile
Name

Jean-Luc Butel

Duration7 years and 8 months
Profile
Name

John Maraganore

Duration4 years and 3 months
Profile
Name

Miki Tsusaka

Duration3 years and 8 months
Profile
Name

Koji Hatsukawa

Duration10 years and 3 months
Profile
Name

Yoshiaki Fujimori

Duration10 years and 3 months
Profile
Name

Kimberly Reed

Duration4 years and 3 months
Profile
Name

Andrew S Plump

Duration11 years and 8 months
Profile
Name

Ian Clark

Duration7 years and 8 months
Profile

 

Director Experience

Name
Experience
Name

Christophe

Experience Pharmaceutical
Profile
Name

Milano

Experience Pharmaceutical
Profile
Name

Costa

Experience Pharmaceutical
Profile
Name

Masami

Experience Pharmaceutical
Profile
Name

Oliver

Experience Medical Equipment, Pharmaceutical
Profile
Name

Jean-Luc

Experience Pharmaceutical, Healthcare, Medical Equipment
Profile
Name

John

Experience Pharmaceutical, Other
Profile
Name

Miki

Experience Pharmaceutical, Professional Firm
Profile
Name

Koji

Experience Financial Services, Pharmaceutical
Profile
Name

Yoshiaki

Experience Pharmaceutical, Technology, Other
Profile
Name

Kimberly

Experience Government, Financial Services, Pharmaceutical
Profile
Name

Andrew S

Experience Pharmaceutical
Profile
Name

Ian

Experience Pharmaceutical
Profile

 

Company Auditors

Name
Date Appointed
Years
Name

KPMG

Date Appointed01/01/2007
Year19 years and 8 months
Profile

 

 

Company Committees

Name

Christophe Weber

Mainboard, Audit, Remuneration BD
Profile
Name

Milano Furuta

Mainboard, Audit, Remuneration BD
Profile
Name

Costa Saroukos

Mainboard, Audit, Remuneration BD
Profile
Name

Masami Lijima

Mainboard, Audit, Remuneration BD
Profile
Name

Oliver Buhuon

Mainboard, Audit, Remuneration BD
Profile
Name

Jean-Luc Butel

Mainboard, Audit, Remuneration BD
Profile
Name

John Maraganore

Mainboard, Audit, Remuneration BD
Profile
Name

Miki Tsusaka

Mainboard, Audit, Remuneration BD
Profile
Name

Koji Hatsukawa

Mainboard, Audit, Remuneration BD, AU
Profile
Name

Yoshiaki Fujimori

Mainboard, Audit, Remuneration BD, AU
Profile
Name

Kimberly Reed

Mainboard, Audit, Remuneration BD, AU
Profile
Name

Andrew S Plump

Mainboard, Audit, Remuneration BD
Profile
Name

Ian Clark

Mainboard, Audit, Remuneration BD
Profile

 

Committee
Abbreviation
Supervisory Board
SB
Board
BD
Risk & Compliance
RC
Audit
AU
Remuneration
RE
Capital investment
CI
Industry Specific
IS
Nominations & Governance
NG
Health, Safety & Environment
HS
Social & Ethics
SE
Technology
TE
Executive
EX
Other
OT